SAM 4132 cropped 2

A new mechanism is being established under Immunization Agenda 2030 (IA2030) to identify regional and country priorities for vaccine research and development (R&D). These priorities will inform Monitoring and Evaluation (M&E) for IA2030. They will also be disseminated widely to enable greater coordination among funders, researchers, vaccine developers, vaccine implementers, and other stakeholders.

The first question being addressed is What are regional and country priorities for vaccine product R&D? Once established, this mechanism can be used for additional questions of interest to regional and global stakeholders.

For more information, email This email address is being protected from spambots. You need JavaScript enabled to view it..

Context and results